Key Takeaways
- Record quarter, margin leap: Q2 FY27 delivered the highest ever quarterly revenue and EBITDA, with EBITDA margin jumping over 300 bps YoY to 37.2%, driven by a 57% surge in the core PFN segment.
- PFN is the engine, Specialty Ingredients the drag: PFN revenue hit ₹142 cr (72% of consolidated) on broad-based pharma demand, while Specialty Ingredients fell 25% YoY after the government's Fortified Rice program was paused.
- The greenfield FDA approval unlocks the next leg: The Nandesari greenfield facility received FDA approval just last week, clearing the path for commercial supplies to begin in H2 FY27 and for new high-value products like magnesium bisglycinate to scale.
- Battery materials is on track, with binding commitments promised soon: Management remains confident in an April 2027 commercial start and expects to share firm binding offtake contracts in Q4, while claiming an 18- to 24-month head start on anyone else that would start working on this now.
- What to watch next quarter: The pace of greenfield customer qualifications converting to orders, the promised binding battery offtake update, and whether Specialty Ingredients returns to positive growth as guided without the Fortified Rice program.
PFN: The Core Growth Engine
- Broad-based, high-margin growth: PFN revenue grew 57% YoY to ₹142 cr, with segment EBITDA nearly doubling and margins expanding to ~41% from 33% YoY, supported by a strong phosphate portfolio and new customer additions across India, Africa, APAC and Europe.
- Volume and value both up: Volume grew 30-35% for the quarter, with phosphates growing closer to 70-80% and magnesium bisglycinate produced at maximum possible capacity in the existing setup.
- Europe traction: A direct commercial presence is now converting customer approvals into regular orders and deepening relationships with existing accounts.
- Utilization is stretched: The existing Nandesari PFN site is operating closer to 80% utilization, slightly stressed higher than optimum, underscoring the urgency of the new greenfield capacity.
- Margin sustainability is cautious: Management does not expect margins to further strengthen from the current ~37% level, citing the need to watch the new contracting cycle and the impending cost burden from greenfield operating costs at low utilization.
Shanil Bhayani: "With growing customer interest, progress in approvals and additional capacity becoming available, we are optimistic that magnesium bisglycinate can become one of the top 3 revenue contributors within PFN over the next 2 to 3 years."
Specialty Ingredients: The Drag, With a Promised H2 Rebound
- Fortified Rice program pause hit hard: Specialty Ingredients revenue fell 25% YoY to ₹54 cr because the Government of India's Fortified Rice program, which typically begins procurement in Aug/Sep, was paused with no visibility on a restart this financial year.
- NSS added to the softness: The NSS subsidiary had a softer quarter with lower revenue and earnings, compounding the segment's decline.
- Margin depressed by operating leverage: The premix business, a large contributor, generated limited revenue, and the drag from NSS further compressed segment margins.
- H2 recovery is contract-backed, not a hope: Management has good visibility into Q3 and Q4 through customer contracts and new approvals from large infant nutrition, dietary supplement and human nutrition customers, and expects Specialty Ingredients to return to positive YoY growth without assuming any restart of the Fortified Rice program.
- Margin recovery expected: Q3 and Q4 margins should improve back to pre-Q2 levels, and new contracts will probably carry a better margin profile than the fortified rice business.
Shanil Bhayani: "Importantly, this expectation is based on customer contracts and new business alone and does not assume a restart of the Fortified Rice program."
Greenfield Facility: FDA Approval Unlocks the Pipeline
- The milestone: The Nandesari greenfield facility received FDA approval during Q2, was capitalized and put to use, with annual capacity of 51,000 tons across the existing PFN portfolio and newer categories including glycinates, gluconates, citrates and phosphates.
- Zero contribution yet: The approval came only last week, so there is no revenue contribution from the new site in Q2 results.
- Ramp-up trajectory: Small quantities are expected in Q3 FY27, with a larger flow from Q4 FY27; FY28 target utilization is closer to 15-20%, ramping to 75% optimum utilization over a 3- to 4-year period with close to 3x asset turnover at that optimum level.
- Higher realization expected: The Nandesari site is expected to operate at a higher realization than the existing site due to its product mix.
- Magnesium bisglycinate capacity relief: Starting Q4, the new capacity should enable a lot more sizable volumes to be supplied to customers in India and globally, with the ingredient alone seen as a ₹100 cr+ revenue opportunity in 2-3 years.
Battery Materials: The Big Bet, De-Risked in Stages
- Competitive moat is real and articulated: Sudeep is the first and only company today producing battery-grade iron phosphate at scale ex-China, using a proprietary green chemistry process that reduces effluent by 90% and solid waste by ~95% versus the conventional Chinese process. Management claims an 18- to 24-month head start on any competitor.
- Why the process advantage matters in India: The conventional Chinese process generates 15,000 liters of effluent per metric ton; getting permission for that volume in India is "close to impossible," and the byproduct has no parallel market, creating a scale limitation beyond 10,000-15,000 tons that Sudeep's process bypasses.
- Customer discussions are advancing faster than expected: Engagements are focused on scaling partnerships with 5 to 7 large Korean customers across Korea, Europe and the U.S., with the number of customer approvals continuing to increase.
- Binding commitments promised in Q4: Management expects to provide a concrete update on firm binding offtake contracts in Q4 FY27, before the April 2027 commissioning, and stated they will be able to break it out by customer and offtakes up to and beyond 100 KTPA.
- Phase 2 and 3 decisions are gated: Expansion beyond the initial 100,000 tons will be based on delivery visibility from binding commitments, though back-end engineering design work is already underway to curtail time to market.
- Pricing strategy is premium, not parity: Sudeep is positioned as an ex-China source operating at a slight premium to Chinese prices; the premium cannot be 100% but will largely be at a price higher than China.
- Investability is defined by asset turns and ROCE, not margin percentage: Management targets similar asset turns (~3x, potentially higher at 200,000 tons) and a similar ROCE profile to the core business (referencing FY26 and earlier levels), and explicitly declined to guide on EBITDA margin for the battery business.
- Raw material supply is secured ex-China: Supplies for up to 100,000 tons are largely secured from India, with geographic diversity from Morocco, Israel, Vietnam and Mexico for 100,000 and 200,000-ton requirements.
Shanil Bhayani: "We are the first and only company today to produce at scale battery grade iron phosphate. We have an indigenous tech, which is proprietary. It is green chemistry, is very competitive on opex, has very good -- and also it is delivering at par product performance."
Shanil Bhayani: "Our goal is not to compete with China. We have positioned Sudeep as an ex-China source which operates at a slight premium. The premium cannot be 100% because you still have to be competitive and the end customer has to be competitive. But it would be -- it would largely be at a price higher than China."
Financial Health: Margins, Returns and the Working Capital Overhang
- Margin walk was strong despite a freight headwind: Gross margin improved to 64.7% from 62.5% YoY, and EBITDA margin rose over 300 bps to 37.2%, even after absorbing ~₹8 cr of elevated selling and distribution expenditure above the normal quarterly average, largely because of freight, to honor customer commitments.
- PAT growth lagged EBITDA: PAT grew only 11% YoY vs. EBITDA's 32% because of lower other income (₹6 cr vs ₹10.2 cr) and a higher effective tax rate (27% vs ~21%) driven by increased depreciation from newly capitalized assets and a revenue mix shift toward PFN, which carries a higher average tax rate of 28%.
- ROCE and ROE are depressed by deployed but idle capital: Annualized ROCE of 22.4% and ROE of 19% reflect capital deployed to the greenfield facility and SAM which are not yet generating revenues; improvement is expected as both commence operations and scale.
- Working capital remains elevated at 214 days: This includes strategic stocking of key raw materials like purified phosphoric acid due to the geopolitical situation, plus some inventory buildup on battery project materials. Management is committed to bringing this down to 170-180 days excluding battery inventory, and to ~150 days over a longer period.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Specialty Ingredients revenue recovery | Return to positive YoY growth, based on customer contracts and new business alone, without assuming Fortified Rice program restart | Q3 and Q4 FY27 |
| Specialty Ingredients margin recovery | Margins to improve back to pre-Q2 levels or levels of the last couple of financial years | Q3 and Q4 FY27 |
| Greenfield PFN commercial supplies | Small quantities to begin, with larger flow thereafter | Q3 FY27 (small), Q4 FY27 (larger) |
| Greenfield PFN utilization ramp | 15-20% utilization target | FY28 |
| Greenfield PFN full ramp | 75% optimum utilization with close to 3x asset turnover | 3- to 4-year period |
| Magnesium bisglycinate revenue | At least ₹100 cr, becoming a top-3 PFN revenue contributor | 2-3 years |
| Battery materials binding offtake update | Concrete update on firm binding contracts, broken out by customer and offtakes up to and beyond 100 KTPA | Q4 FY27 |
| Battery materials commercial operations | Commence commercial operations | April 2027 |
| Battery materials Phase 1 revenue | Commercial supplies and revenue generation begin, assuming ~6 months for customer site validation post-commissioning | H2 FY28 |
| Battery materials Phase 2/3 decision | Gated by delivery visibility from binding commitments | Post binding commitments |
| NSS performance | Flattish year; growth at a similar pace to core business growth; target EBITDA margin close to 30%, barring supply-side shocks | FY27 (flattish), FY28 (growth) |
| Working capital reduction | 170-180 days, excluding battery materials inventory | FY27 |
| Working capital long-term target | ~150 days | Longer period |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue from operations | ₹196.7 cr, +21% YoY and +24% QoQ |
| EBITDA | ₹73.2 cr, +32% YoY and +33% QoQ |
| EBITDA margin | 37.2%, +310 bps YoY (34.1% in Q2 FY26) |
| Gross margin | 64.7%, vs 62.5% in Q2 FY26 |
| PAT | ₹51.8 cr, +11% YoY |
| PAT margin | 26.3% |
| Effective tax rate | 27%, vs ~21% in Q2 FY26 |
| Other income | lower by ₹6 cr vs ₹10.2 cr in Q2 FY26 |
| Pharma Food Nutrition revenue | ₹142 cr, +57% YoY, ~72% of consolidated revenue |
| PFN segment EBITDA margin | ~41%, vs 33% in Q2 FY26; segment EBITDA nearly doubled |
| Specialty Ingredients revenue | ₹54 cr, +9% QoQ, -25% YoY |
| Export share | ~65% of revenue; exports grew 24% YoY |
| Net working capital days | 214 days as of 30 Sep 2026, similar to March 2026 |
| Net debt | ₹72.5 cr, net debt-to-equity 0.07x (vs ₹33.6 cr and 0.04x as of 31 Mar 2026) |
| Annualized ROCE (H1 FY27) | 22.4% |
| Annualized ROE (H1 FY27) | 19% |
| Capex in FY27 | ~₹77 cr, mainly towards Battery Materials and greenfield facility completion |
| Cash flow from operations (H1 FY27) | ₹43.5 cr, up ₹26 cr YoY |
| Selling & distribution expenditure | ~₹8 cr above normal quarterly average, largely because of freight |
| Greenfield facility capacity (Nandesari) | 51,000 tons annual capacity; FDA approval received during the quarter; customer qualifications underway, commercial supplies expected H2 FY27 |
| Magnesium bisglycinate average realization | >3x the average of PFN portfolio |
| Battery Materials Phase 1 capacity | 25,000 tons of battery-grade iron phosphate; commercial operations expected April 2027 |